Clinical study of lenvatinib on 4 cases of RAI refractory differentiated thyroid carcinoma-Reference-Cited by-同舟云学术

Clinical study of lenvatinib on 4 cases of RAI refractory differentiated thyroid carcinoma

Published:2018 Issue:1 Volume:44 Page:51-56
ISSN:1349-5747
Container-title:Toukeibu Gan
language:en
Short-container-title:Toukeibu Gan

Author:

Shirakura Satoshi¹,Sugimoto Taro¹,Eguchi Kotaro¹,Mukai Masayoshi¹,Yamazaki Ayame²,Tanabe Ayumi³,Asakage Takahiro⁴

Affiliation:

1. Department of Otorhinolaryngology, Head and Neck surgery, Tokyo Metropolitan Cancer and infectious Diseases Center Komagome Hospital

2. Department of Otorhinolaryngology, Head and Neck surgery, Tokyo Metropolitan Health and Medical Treatment Corporation Ohkubo Hospital

3. Department of Otorhinolaryngology, pediatric Otorhinolaryngology, Tokyo Women’s Medical University Yachiyo Medical Center

4. Department of Head and Neck surgery, Tokyo Medical and Dental University

Publisher

Japan Society for Head and Neck Cancer

Subject

Oncology,Otorhinolaryngology

Link

https://www.jstage.jst.go.jp/article/jjhnc/44/1/44_51/_pdf

Reference13 articles.

1. 1） Ito Y., Miyauchi A., Ito M., et al: Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy. Endocrine Journal 61：821-824, 2014

2. 2） Durante C., Haddy N., Baudin E., et al: Long-Term Outcome of 444 Patients with Distant Metastases from papillary and Follicular Thyroid carcinoma: Benefits and Limits of Radioiodine Therapy. J Clin Endocrinol Metab 91：2892-2899, 2006

3. 3）平野　滋，中野　宏，松井雅裕，他：甲状腺癌の薬物治療 up-to-date　日耳鼻　120：1140-1146，2017

4. 4） National Comprehensive Cancer Network, NCCN clinical practice in oncology for thyroid carcinoma. Ver2. 2015, ［online］ http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#thyroid.

5. 5） Schlumberger M., Tahara M., Wirth L.J., et al: Lenbatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372：621-630, 2015